PACB — Pacific Biosciences of California, Inc.

Summary of PACB Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $38.4 million, slightly below expectations (compared to $40 million in Q3 2024).
• Instrument Revenue: $11.3 million, a 33% decrease year-over-year and 20% decrease sequentially.
• Consumable Revenue: Record high of $21.3 million, up 15% year-over-year and 12% sequentially.
• Non-GAAP Gross Margin: 42%, the highest since 2022, up from 33% in Q3 2024.
• Non-GAAP Net Loss: $36.8 million ($0.12 per share), improved from a loss of $46 million ($0.17 per share) in Q3 2024.
• Cash Position: $298.7 million in unrestricted cash and investments, down from $389.9 million at year-end 2024.

2. Strategic Updates and Business Highlights

• Product Shipments: 13 Revio systems and 32 Vega systems shipped in Q3, with 75% of Revio shipments to new customers.
• Strong Consumable Demand: Driven by broad adoption of SPRQ Chemistry and high utilization rates across the installed base.
• Regulatory Approval: Sequel II CNDx system received Class III Medical Device Registration approval in China, marking a significant milestone for clinical-grade long-read sequencing.
• New Product Launches: Introduction of the PureTarget portfolio for challenging genomic regions and SPRQ-Nx chemistry aimed at reducing sequencing costs.

3. Forward Guidance and Outlook

• Q4 Expectations: Anticipated revenue growth of approximately 10% sequentially, driven by increased Revio and Vega placements.
• Full-Year 2025 Revenue Guidance: Narrowed to between $155 million and $160 million.
• Cash Burn: Expected to total approximately $115 million for 2025, significantly improved from 2024.
• Long-Term Goal: Aiming for cash flow breakeven by the end of 2027.

4. Bad News, Challenges, or Points of Concern

• Instrument Revenue Decline: Significant drop in instrument revenue due to lower Revio shipments and procurement delays for Vega systems, particularly in Europe.
• Funding Environment: Continued challenges in the academic and government research sectors, with elongated procurement cycles expected to persist into 2026.
• Competitive Pressures: Potential risks from new entrants in the sequencing market, particularly in clinical applications.
• Government Shutdown Impact: Although not yet material, prolonged shutdown could affect future order volumes, especially in NIH-funded sectors.

5. Notable Q&A Insights

• ASP Trends: Revio average selling prices (ASPs) were lower in Q3 but expected to recover in Q4; Vega ASPs remained stable.
• Vega System Delays: Procurement issues in Europe resulted in delayed shipments, but orders are expected to be fulfilled in Q4.
• Clinical Applications Growth: Strong traction in clinical applications is anticipated to offset challenges in academic funding.
• SPRQ-Nx Chemistry: Expected to enhance revenue growth and improve margins by allowing multiple uses of SMRT Cells, with beta testing set to begin soon.
• Population Scale Programs: Increased interest in large-scale studies following the SPRQ-Nx announcement, with potential for significant new revenue streams.

This summary encapsulates the key points from the earnings call, providing a clear overview of PacBio's current financial health, strategic direction, and challenges moving forward.